MARIMED (MRMD) SEC Filings

Marimed Inc. Chief Financial Officer Mario Pinho converted 38,282 RSUs into 38,282 common shares on October 15, 2026, on a one-for-one basis. The issuer withheld 11,236 shares to satisfy tax withholding obligations at $0.06 per share; Pinho held 76,562 RSUs following the transaction.

Marimed Inc. President and CEO Jon R. Levine converted 30,625 restricted stock units into 30,625 common shares on October 15, 2026, on a one-for-one basis. The issuer withheld 8,989 shares to satisfy tax withholding obligations tied to vesting, at a reported $0.06 per share. 61,250 RSUs remained following the transaction. A separate holding entry lists 6,684,640 common shares held by Levine’s spouse; Levine disclaims beneficial ownership of those shares.

Marimed Inc. (MRMD) Chief Commercial Officer Ryan Crandall exercised 32,812 restricted stock units on October 15, 2026, converting them one-for-one into common stock. The issuer withheld 9,631 common shares to satisfy tax obligations tied to vesting, reported at $0.06 per share. Crandall's reported post-transaction position was 65,625 RSUs.

MariMed Inc. (MRMD) Chief Operating Officer Timothy Shaw converted 9,981 RSUs into 9,981 common shares on October 2, 2026. The issuer withheld 3,459 shares for tax withholding obligations at $0.0696 per share. The transaction reports 9,982 RSUs following conversion; the remaining RSUs under the grant will vest in full on April 2, 2027. Separately, the Shaw Family Trust held 2,000,000 common shares; Shaw's spouse is trustee, the shares benefit his children, and Shaw disclaims beneficial ownership.

On October 2, 2026, Marimed Inc. President and CEO Jon R. Levine converted 11,517 restricted stock units into 11,517 common shares on a one-for-one basis. The issuer withheld 3,991 shares to satisfy tax-withholding obligations tied to vesting; no Rule 10b5-1 plan is reported. Christine A. Levine, Jon R. Levine’s spouse, holds 6,684,640 shares, and Jon R. Levine disclaims beneficial ownership of them.

At MariMed Inc., Chief Commercial Officer Ryan Crandall converted 6,046 RSUs into 6,046 common shares on September 28, 2026, on a one-for-one basis. The issuer withheld 2,095 common shares to satisfy tax withholding obligations, at a reported price of $0.077 per share. The reported RSU position following the transaction was 6,047 shares.

MariMed Inc. filed a definitive proxy statement seeking stockholder approval of a proposed reverse split of its common stock. If approved, the proposal would authorize the board to choose a ratio between one-for-50 and one-for-100 and decide whether and when to implement it; the board could also decide not to proceed. No fractional shares would be issued, with cash paid instead for fractional interests.

MariMed says the proposal is intended to provide flexibility to meet minimum share-price and other requirements for a potential U.S. national securities exchange listing. The special meeting is scheduled virtually for October 28, 2026, at 9:30 a.m. Eastern time; shareholders of record at close of business September 4, 2026, may vote. The company says there is no assurance it will implement the split, qualify for a listing, satisfy all listing requirements, or that the split will result in a sustained increase in trading price or liquidity.

MariMed Inc. (MRMD) is calling a virtual special stockholders’ meeting on October 28, 2026 to vote on a significant capital structure change and a related procedural item. The main proposal would amend the Certificate of Incorporation to authorize a reverse stock split of the common stock at a ratio between 1‑for‑50 and 1‑for‑100, to be selected later by the board in its sole discretion, without reducing the authorized number of common shares. Cash would be paid in lieu of fractional shares. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.

The board states that the purpose of the reverse split is to raise the share price to help meet NYSE American or Nasdaq minimum bid price requirements and potentially broaden institutional ownership and analyst coverage. As of the September 4, 2026 record date, there were 403,740,510 common shares outstanding; at a 1‑for‑100 split, this would drop to about 4.0 million outstanding shares. Because the authorized share count would remain unchanged, the transaction would materially increase the number of authorized but unissued shares, which could be used for future issuances and may have anti‑takeover implications. The company highlights risks that the split may not produce or sustain the desired price level, may reduce liquidity and create more odd‑lot holdings, and that U.S. federal cannabis laws and exchange policies may still prevent an up‑listing even if price requirements are met.

MariMed Inc. (MRMD) is calling a special shareholder meeting on October 28, 2026 to seek approval to amend its Certificate of Incorporation to implement a reverse stock split of its common stock at a ratio between 1-for-50 and 1-for-100, at the board’s discretion, without reducing the number of authorized shares. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.

The reverse split is intended mainly to raise the share price to help qualify for a potential listing on NYSE American or Nasdaq and to broaden institutional and analyst interest. MariMed notes material risks: the price may not rise proportionally or sustainably, liquidity could decline, odd-lot holdings and trading costs may increase, and U.S. federal cannabis law and exchange policies may still prevent a U.S. exchange listing even if price thresholds are met.

If implemented, outstanding common shares would shrink from 403,740,510 to as few as about 4.0 million at 1-for-100, with cash paid in lieu of fractional shares. Authorized common and preferred share counts, voting and dividend rights, and par values would be unchanged, increasing the pool of authorized but unissued shares that the board could issue in the future, which the company acknowledges could have anti-takeover implications.